Allogene Therapeutics Appoints Geoffrey Parker As Chief Financial Officer
Portfolio Pulse from Benzinga Newsdesk
Allogene Therapeutics, Inc. (NASDAQ:ALLO) has appointed Geoffrey Parker as its new Executive Vice President, Chief Financial Officer. Parker, who has nearly 40 years of leadership experience in biotech and banking, will oversee the company's financial operations and business strategy. Prior to joining Allogene, Parker served as CFO of Tricida, Inc. and Anacor Pharmaceuticals, and as a Managing Director at Goldman Sachs.
October 16, 2023 | 12:46 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Geoffrey Parker's appointment as CFO could bring positive changes to Allogene Therapeutics, given his extensive experience in finance and business development strategy in the biotech sector.
Geoffrey Parker's extensive experience in finance and business development strategy in the biotech sector could potentially lead to positive changes in Allogene Therapeutics' financial operations and business strategy, which could positively impact the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100